Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes

European Journal of Endocrinology

Volumn 159, Issue 6, 2008, Pages 739-746

  Stanworth, R D ^a,b   Kapoor, D ^a,b   Channer, K S ^c,d   Jones, T Hugh ^a,b  

^a BARNSLEY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTRADIOL; GONADOTROPIN; HEMOGLOBIN A1C; INSULIN; LEPTIN; LUTEINIZING HORMONE; ORAL ANTIDIABETIC AGENT; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC DIET; GENERAL HOSPITAL; GENETIC POLYMORPHISM; GLYCEMIC CONTROL; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TRINUCLEOTIDE REPEAT; WAIST CIRCUMFERENCE; BLOOD; COMPARATIVE STUDY; GENETICS;

ADULT; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; LEPTIN; MALE; OBESITY; POLYMORPHISM, GENETIC; RECEPTORS, ANDROGEN; TESTOSTERONE; TRINUCLEOTIDE REPEATS;

EID: 58149343861     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0266     Document Type: Article

References (40)

1. Kapoor D, Malkin CJ, Channer KS & Jones TH. Androgens, insulin resistance and vascular disease in men, Clinical Endocrinology 2005 63 239-250.
2. Andersson B, Marin P, Lissner L, Vermeulen A & Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994 17 405-411.
3. Kapoor D, Aldred H, Clark S, Charmer KS & Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007 30 911-917.
4. Haffner SM, Shaten J, Stern MP. Smith GD & Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. American Journal of Epidemiology 1996 143 889-897.
5. Oh JY, Barrett-Connor E, Wedick NM & Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002 25 55-60.
6. Tibblin G, Adlerberth A, Lindstedt G & Bjorntorp P. The pituitary-gonadal axis and health in elderly men: a study of men born in 1913. Diabetes 1996 45 1605-1609.
7. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R & Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004 27 1036-1041.
8. Stellato RK, Feldman HA, Hamdy O, Horton ES & McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000 23 490-494.
9. Kapoor D, Goodwin E, Channer KS & Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology 2006 154 899-906.
10. Simon D, Charles MA, Lahlou N, Nahoul K, Oppert JM, Gouault-Heilmann M, Lemort N, Thibult N, Joubert E, Balkan B & Eschwege E. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care 2001 24 2149-2151.
11. Zimmet P, Hodge A, Nicolson M, Staten M, de Courten M, Moore J, Morawiecki A, Lubina J, Collier G, Alberti G & Dowse G. Serum leptin concentration, obesity, and insulin resistance in Western Samoans: cross sectional study. BMJ 1996 313 965-969.
12. Kapoor D, Clarke S, Stanworth R, Channer KS & Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. European Journal of Endocrinology 2007 156 595-602.
13. Klocker H, Gromoll J & Cato ACB. The androgen receptor: molecular biology. In Testosterone. Action, Deficiency, Substitution, pp 39-92. Ed. HM Behre, Cambridge, UK: Cambridge University Press, 2004.
14. Chamberlain NL, Driver ED & Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Research 1994 22 3181-3186.
15. Beilin J, Ball EM, Favaloro JM & Zajac JD. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. Journal of Molecular Endocrinology 2000 25 85-96.
16. Zeegers MP, Kiemeney LA, Nieder AM & Ostrer H. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiology, Biomarkers and Prevention 2004 13 1765-1771.
17. Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn TA, Mostoli FK, Benichou J & Chang C. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Research 2000 60 5111-5116.
18. Giovannucci E, Stampfer MJ, Chan A, Krithivas K, Gann PH, Hennekens CH & Kantoff PW. CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in US physicians. Prostate 1999 39 130-134.
19. Mitsumori K, Terai A, Oka H, Segawa T, Ogura K, Yoshida O & Ogawa O. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. Prostate 1999 41 253-257.
20. Zitzmann M, Depenbusch M, Gromoll J & Nieschlag E. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study, Journal of Clinical Endocrinology and Metabolism 2003 88 2049-2054.
21. Krithivas K, Yurgalevitch SM, Mohr BA, Wilcox CJ, Batter SJ, Brown M, Longcope C, McKinlay JB & Kantoff PW. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. Journal of Endocrinology 1999 162 137-142.
22. von Eckardstein S, Syska A, Gromoll J, Kamischke A, Simoni M & Nieschlag E. Inverse correlation between sperm concentration and number of androgen receptor CAG repeats in normal men. Journal of Clinical Endocrinology and Metabolism 2001 86 2585-2590.
23. Mifsud A, Sim CK, Boettger-Tong H, Moreira S, Lamb DJ, Lipshultz LI & Yong EL. Trinucleotide (CAG) repeat polymorphisms in the androgen receptor gene: molecular markers of risk for male infertility Fertility and Sterility 2001 75 275-281.
24. Zitzmann M, Brune M, Kornmann B, Gromoll J, Junker R & Nieschlag E. The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clinical Endocrinology 2001 55 649-657.
25. Zitzmann M, Depenbusch M, Gromoll J & Nieschlag E. X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. Journal of Clinical Endocrinology and Metabolism 2004 89 6208-6217.
26. Mariotti C, Castellotti B, Pareyson D, Testa D, Eoli M, Antozzi C, Silani V, Marconi R, Tezzon F, Siciliano G, Marchini C, Gellera C & Donato SD. Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromuscular Disorders 2000 10 391-397.
27. Zitzmann M, Gromoll J, von Eckardstein A & Nieschlag E. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia 2003 46 31-39.
28. Walsh S, Zmuda JM, Cauley JA, Shea PR, Metter EJ, Hurley BF, Ferrell RE & Roth SM. Androgen receptor CAG repeat polymorphism is associated with fat-free mass in men. Journal of Applied Physiology 2005 98 132-137.
29. Van Pottelbergh I, Lumbroso S, Goemaere S, Sultan C & Kaufman JM. Lack of influence of the androgen receptor gene CAG-repeat polymorphism on sex steroid status and bone metabolism in elderly men. Clinical Endocrinology 2001 55 659-666.
30. Zitzmann M, Brune M, Kornmann B, Gromoll J, von Eckardstein S, von Eckardstein A & Nieschlag E. The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. Journal of Clinical Endocrinology and Metabolism 2001 86 4867-4873.
31. 2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology 2006 147 2675-2680.
32. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D & Perry HM. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000 49 1239-1242.
33. Tremblay RR & Dube JY. Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. Contraception 1974 10 599-605.
34. Vermeulen A, Rubens R & Verdonck L. Testosterone secretion and metabolism in male senescence. Journal of Clinical Endocrinology and Metabolism 1972 34 730-735.
35. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G & Bjorntorp P. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. International Journal of Obesity and Related Metabolic Disorders 1992 16 991-997.
36. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A & Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clinical Endocrinology 2005 63 280-293.
37. Nettleship JE, Jones TH, Channer KS & Jones RD. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation 2007 116 2427-2434.
38. Jones TH. Hypogonadism in men with type 2 diabetes. Practical Diabetes International 2007 24 269-277.
39. Sartor O, Zheng Q & Eastham JA. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology 1999 53 378-380.
40. Stanworth RD, Kapoor D, Channer KS & Jones TH. Statin use is associated with lower total testosterone levels but not bioavailable or free testosterone in men with type 2 diabetes. Diabetic Medicine 2007 24 P135.